ARTICLE | Clinical News

Suglat ipragliflozin regulatory update

January 20, 2014 8:00 AM UTC

Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Suglat ipragliflozin to treat Type II diabetes - the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat with Kotobuki. Astellas, Kotobuki and the MSD K.K. subsidiary of Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) will co-promote the product in Japan. ...